Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Ojemda (tovorafenib)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Day One Biopharma, Ipsen, Takeda, Xoma

Drug class:

pan-RAF inhibitor

Related drugs:

BRAF fusion	Glioma	BRAF fusion	Glioma	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1
BRAF V600	Glioma	BRAF V600	Glioma	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1
BRAF rearrangement	Glioma	BRAF rearrangement	Glioma	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1	tovorafenib Sensitive: A1 - Approval tovorafenib Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	tovorafenib Sensitive: B - Late Trials tovorafenib Sensitive : B	tovorafenib Sensitive: B - Late Trials tovorafenib Sensitive : B
BRAF mutation	Glioma	BRAF mutation	Glioma	tovorafenib Sensitive: C2 – Inclusion Criteria tovorafenib Sensitive : C2	tovorafenib Sensitive: C2 – Inclusion Criteria tovorafenib Sensitive : C2
BRAF mutation	Melanoma	BRAF mutation	Melanoma	tovorafenib Sensitive: C3 – Early Trials tovorafenib Sensitive : C3	tovorafenib Sensitive: C3 – Early Trials tovorafenib Sensitive : C3
BRAF V600E	Glioma	BRAF V600E	Glioma	tovorafenib Sensitive: C3 – Early Trials tovorafenib Sensitive : C3	tovorafenib Sensitive: C3 – Early Trials tovorafenib Sensitive : C3
TRIM33-BRAF fusion	Melanoma	TRIM33-BRAF fusion	Melanoma	tovorafenib Sensitive: C4 – Case Studies tovorafenib Sensitive : C4	tovorafenib Sensitive: C4 – Case Studies tovorafenib Sensitive : C4
AGK-BRAF fusion	Melanoma	AGK-BRAF fusion	Melanoma	tovorafenib Sensitive: C4 – Case Studies tovorafenib Sensitive : C4	tovorafenib Sensitive: C4 – Case Studies tovorafenib Sensitive : C4